Ocugen (OCGN) Expected to Announce Earnings on Wednesday

Ocugen (NASDAQ:OCGN) is anticipated to release its earnings data before the market opens on Wednesday, March 5th. Analysts expect Ocugen to post earnings of ($0.05) per share and revenue of $0.30 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Ocugen Trading Down 3.9 %

Shares of OCGN opened at $0.61 on Wednesday. The stock has a market capitalization of $176.31 million, a P/E ratio of -3.36 and a beta of 3.82. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.04. The firm has a fifty day simple moving average of $0.75 and a two-hundred day simple moving average of $0.94. Ocugen has a twelve month low of $0.60 and a twelve month high of $2.11.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on OCGN shares. Chardan Capital reissued a “buy” rating and set a $6.00 price target on shares of Ocugen in a research report on Thursday, February 13th. HC Wainwright increased their price target on shares of Ocugen from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, February 13th.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.